Rescue in immune-mediated alopecia
目标: This presentation evaluates exosome therapy for immune-mediated alopecia within the ERK→AKT→FOXO3a signaling continuum. Alopecia areata and lichen planopilaris are framed as dynamic signaling states in which therapeutic timing influences outcomes. The discussion proposes a phase-conscious strategy positioning exosomes as regulators of immune tolerance, oxidative resilience, and follicular stabilization rather than simple growth stimulants.
介绍: To propose a phase-conscious framework to use regenerative biologics in immune-mediated alopecia. The model distinguishes active immune injury, a repair window, and stability along an ERK-AKT-FOXO3a signaling continuum. It compares alopecia areata, where bulb-directed inflammation often leaves the stem-cell reservoir intact, with lichen planopilaris, where bulge injury may destroy that reservoir and induce fibrosis. It defines why immune control should precede PRP, why adipose support requires a stable recipient bed, and why extracellular vesicles belong later, for a clearly specified purpose.
材料 / 方法: A structured narrative review integrated mechanistic, histopathologic, preclinical, clinical, consensus, and regulatory literature on alopecia areata, lichen planopilaris, follicular stem-cell biology, PRP, adipose, extracellular vesicles, and ERK-AKT-FOXO3a signaling. Evidence was organized by disease target, follicular viability, inflammatory activity, reversibility, product definition, and maturity. These domains were used to construct a three-gate sequence: control active immunity, test repair with the least durable intervention, then stabilize with a clear purpose and a surveillance plan.
结果: The synthesis supports a shared sequence but different biological ceilings. In alopecia areata, preserved bulge stem cells leave regenerative potential after immune control. In lichen planopilaris, loss of the bulge niche and fibrosis can make regrowth anatomically impossible, despite reduced inflammation. PRP is the rational first repair pulse because it is autologous, transient, adjustable, and observable. Adipose may add matrix, stromal, vascular, and paracrine support after stability. Extracellular vesicles are heterogeneous; no validated AA or LPP product, dose, route, or schedule exists.
总结: Treat immune-mediated alopecia as a changing tissue state, not a request for an injectable. First suppress disease and document stability. Next use PRP as a reversible test of follicular responsiveness. Add adipose only when a stable recipient bed still needs matrix, vascular, or stromal reconstruction. Consider defined extracellular vesicles later for transition or maintenance, with product characterization and surveillance. This framework preserves optionality, respects the irreversible ceiling created by LPP fibrosis, and prevents regenerative signaling from substituting for immune control.
